Mid-size Pharma CHDI Management, Inc. operates in the pharmaceutical manufacturing space with a modest team size (11-50 employees) and a revenue range of $25M-$50M, indicating a lean organization potentially open to strategic partnerships, contract development and manufacturing (CDMO) opportunities, or technology licensing that can scale without large internal procurement frictions.

Strategic Location Headquartered in New York City at 350 7th Ave, CHDI’s proximity to dense pharma, biotech, and healthcare hubs may enable collaboration with nearby contract manufacturers, analytical labs, and specialty suppliers, offering sales reps a chance to position value through expedited support, local regulatory navigation, and faster onboarding.

Therapeutic Focus While explicit therapeutic areas aren’t listed, CHDI’s operation within Pharmaceuticals and comparable revenue peers suggest potential engagement in neurodegenerative or specialized therapeutic programs, making them a candidate for high-value GMP services, analytical development, and fill-finish capabilities that cater to niche markets.

Growth & Partnerships With a revenue band similar to peer organizations like CurePSP and a mid-sized employee base, there is room for channel partnerships, co-development ventures, or service expansions (cdmo, quality systems, regulatory affairs support) to help scale operations and broaden product pipelines.

Decision-Maker Signals The absence of detailed funding rounds and recent news suggests a focus on steady operations; sales outreach can target senior operations, manufacturing leadership, and procurement decision-makers to discuss cost efficiencies, supply reliability, and scalable manufacturing agreements that align with their revenue profile.